TMEM97 and cancer: Cells were also exposed to a single dose of siramesine (10 μM), a sigma-2 receptor ligand, which was shown to induce lysosomal membrane permeabilization (LMP) leading to cell death; hence, siramesine was suggested as a novel anticancer compound that targets lysosomes in cancer cells [31, 32].